NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

New York, January 12, 2026, 05:15 EST — Premarket

  • Shares of NovaBay Pharmaceuticals slipped roughly 10% in premarket action.
  • The stock surged past double its previous level on Friday, trading about 10 million shares.
  • Traders are eager for new updates on warrants, conversions, and the share supply.

NovaBay Pharmaceuticals, Inc. shares slipped roughly 10% in early Monday trading, falling to $17.21 after finishing Friday at $19.16. This dip comes after a notable surge in the lightly traded stock on the NYSE American. Stockanalysis

Friday’s surge was extreme, even for a microcap. Shares closed up 102.5%, swinging between $9.69 and $19.95, on roughly 10 million shares changing hands, according to StockAnalysis data. Stockanalysis

This is crucial now, as the stock has morphed into a momentum play within just a few sessions. Such trades hinge heavily on share availability. With thin liquidity, prices can jump sharply on minimal volume—and then flip direction just as quickly.

According to StockAnalysis data, the 20-day average volume stands near 3.0 million shares, with the float hovering around 12.4 million shares. This combination often magnifies both squeezes and selloffs during volume surges. Stockanalysis

Traders keep focusing on the company’s capital structure. In an October filing, NovaBay revealed it sold pre-funded warrants for roughly 5.4 million shares, exercisable after Jan. 1, 2026, pending stockholder approval. The company also noted shareholders authorized the board to execute a reverse stock split anywhere from 1-for-2 up to 1-for-10. Sec

NovaBay revealed in its latest quarterly filing that it had once considered winding down but decided against it. The company is now exploring a pivot toward “emerging financial infrastructure and network-based markets,” with a particular interest in select blockchain-based assets. It also noted that its cash reserves should cover operating costs through at least Nov. 7, 2026. Sec

NovaBay hasn’t released any new comments on the recent stock moves, leaving traders to interpret volume, spreads, and any upcoming disclosures ahead of the open.

But the setup works both ways. Pre-market trading often sees thin volume and wider spreads. Plus, any hint that more shares might enter the market—whether from warrant exercises, preferred stock conversions, or other issuances—can quickly shift the equation for a stock that’s already surged dramatically in a short span.

When the regular session kicks off at 9:30 a.m. EST, traders will focus on whether the stock can maintain last week’s key levels and if the volume remains strong or tapers off.

NovaBay’s fourth-quarter 2025 earnings are expected to drop on March 25, according to MarketScreener. Marketscreener

Stock Market Today

  • FormFactor (NASDAQ:FORM) Receives 'Moderate Buy' Consensus; Analysts Raise Price Targets
    February 2, 2026, 11:09 AM EST. FormFactor, Inc. (NASDAQ:FORM) holds an average analyst rating of 'Moderate Buy' based on 12 firms covering the stock, including 5 buy and 6 hold recommendations. The current consensus 1-year target price stands at $64.11, reflecting raised expectations after recent upgrades by firms like Stifel Nicolaus and Itau BBA Securities. Insider selling was active, with CEO Mike Slessor reducing his stake by 7.54%, disposing of shares valued over $2.5 million at $65 each. Director Kelley Steven-Waiss also cut holdings by 7.61%. Despite this, insiders retain about 0.96% ownership. Hedge funds such as Jones Financial Companies increased exposure significantly. Market participants remain cautiously optimistic amid mixed analyst views and notable insider transactions.
Barclays stock slides on Trump’s 10% credit-card rate cap call as investors size up profit hit
Previous Story

Barclays stock slides on Trump’s 10% credit-card rate cap call as investors size up profit hit

Mereo BioPharma stock steadies premarket as JPM Healthcare Conference puts MREO back in play
Next Story

Mereo BioPharma stock steadies premarket as JPM Healthcare Conference puts MREO back in play

Go toTop